Document is current
Any future updates will be listed below
-
Authors
Wiedmeier-Nutor, J. E.
Kosiorek, H. E.
Arribas, M. https://orcid.org/0000-0003-1859-7098
Simmons, H.
Jacob, A.
Bhattu, S. S.
Fonseca, R. https://orcid.org/0000-0001-7130-0340
Bruins, L.
Ahmann, G.
Yadav, U.
Chhabra, S. https://orcid.org/0000-0001-9117-8696
Bergsagel, P. L. https://orcid.org/0000-0003-1523-7388
Fonseca, R. https://orcid.org/0000-0002-5938-3769
- License Information
-
More Information
Article History
Received: 23 December 2025
Revised: 16 March 2026
Accepted: 14 April 2026
First Online: 30 April 2026
Conflict of interest
: Adaptive Biotechnologies processed all peripheral blood samples. RF Consulting: AbbVie, Adaptive, Amgen, Apple, BMS/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi; Scientific Advisory Board: Caris Life Sciences; Board of Directors: AntengenePatent for FISH in MM - ~$2000/year. HS reports stock ownership in Adaptive Biotechnologies. AJ is an employee and stockholder of Adaptive Biotechnologies. SC: Honorarium: Sanofi, Sobi, Ascentage Pharma, BMS, Pfizer, AstraZeneca, Legend Biotech; Institutional Research Funding: C4 Therapeutics, CARSgen, Cynata Therapeutics, Johnson & Johnson, Ascentage Pharma, AstraZeneca, Incyte, Abbvie, Simcere, Cullinan Therapeutics, National Marrow Donor Program; LB: Consulting: Oncopeptides, Salarius Pharmaceuticals, Radmetrix International, Omeros Corporation, CellCentric Limited, Abbvie, Pfizer, Cancer Network; Licensed Intellectual Property: Genetically Engineered Mouse Models of Multiple Myeloma (including IMiD-responsive models), Active Licensing agreements involving Novartis, Pfizer, Opna Bio, including royalty-bearing arrangements.
